Shares of MAP Pharmaceuticals Inc. (Nasdaq: MAPP) soared $5.78 to $8.93 after its migraine drug treatment met late-stage study goals.
MAP's Migraine Drug Meets Study Goals
May 26, 2009 at 13:06 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.